



Altimune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

February 26, 2026 at 7:30 AM EST

GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- [Altimune, Inc.](#) (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its fourth quarter 2025 financial results on Thursday, March 5, 2026.

Altimune management will host a conference call at 8:30 a.m. ET on March 5 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimune's Investor Relations website at <https://ir.altimmune.com/investors>.

Participants who would like to join the call may register [here](#) to receive dial-in numbers and a unique PIN. A replay will be available on the Investor Relations website shortly after the call for up to three months.

About Altimune

Altimune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's lead candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.

Follow @Altimune, Inc. on [LinkedIn](#)

Follow @AltimuneInc on [X](#)

Investor Contact:

Lee Roth
Burns McClellan
lroth@burnsmc.com

Media Contact:

Real Chemistry
altimmune@realchemistry.com

This press release was published by a CLEAR® Verified individual.



altimmune

Source: Altimune, Inc